Estrogen plays a crucial role in embryonic and fetal development by influencing female secondary sexual characteristics, reproductive cycle, fertility, and maintenance of pregnancy. 3 Estrogen exerts its effects by binding to the estrogen receptors alpha (ESR1) and beta (ESR2) that, once activated, regulate the expression of multiple genes. 4 Both ESR1 and ESR2 genes are expressed in the human ovary, 5 within the oocyte, 6 in granulosa cells, 7 and in ovarian epithelial cells. 8 Numerous polymorphisms in genes coding for ESR1 and ESR2 have been described. 9 Sundarrajan et al 10 associated the c.454-397T>C polymorphism in the ESR1 gene with ovarian follicular development and subsequently with pregnancy rate. ESR2 polymorphisms have been related to decreases in the serum level of luteinizing hormone, follicle-stimulating
R ecurrent miscarriage (RM) is defined as 3 or more consecutive pregnancy losses and occurs in approximately 1% to 2% of couples. 1 The etiologies of RM are heterogeneous, and a definite cause is found in less than half of the cases. Possible causes reported include genetic anomalies, anatomical disorders, hormonal abnormalities, and thrombophilia. 2 The aim of this study was to determine the prevalence of alpha (ESR1: c.454-397T>C and c.454-351A>G) and beta (ESR2: 1082G>A and 1730G>A) estrogen receptor gene polymorphisms in 2 Brazilian ethnic groups (Caucasian, African Brazilian) and to investigate their association with recurrent miscarriage (RM) in 75 women with a history of 3 or more consecutive pregnancy losses and 139 controls with at least 2 live births and no history of pregnancy loss. Polymerase chain reaction and restriction fragment length polymorphism were used to identify gene polymorphisms. Coagulation methods were used to measure protein C, protein S, and fibrinogen, and a chromogenic method was used for antithrombin quantification. Significantly higher prevalences of 1082G>A and 1730G>A polymorphisms were seen in African Brazilian and Caucasian controls, respectively. There was no association between RM and ESR polymorphisms. There was a difference in the genotype prevalence in the c.454-39T>C polymorphism between RM and control Caucasians, but this finding was not associated with an increased risk of miscarriage. There was no synergistic or additive effect between ESR polymorphisms and thrombophilia in RM patients. A difference in the prevalence of ESR polymorphisms was observed, according to ethnic origin. ESR polymorphisms could not be considered a risk factor for RM. Keywords: recurrent miscarriage; estrogen receptors; polymorphisms hormone, and progesterone in women with ovulatory dysfunctions. 11 Previous reports investigated the B region in the ESR1 gene in primary and secondary recurrent spontaneous abortion, 12 but no study has analyzed other polymorphisms in the ESR1 and ESR2 genes.
The aim of this study was to determine genotype prevalence of ESR polymorphisms in a Brazilian population. We hypothesized that the presence of these polymorphisms could induce alterations in estrogen levels that could interfere with pregnancy maintenance and determined whether these polymorphisms and haplotypes could predict the risk for RM. Because hemostasis may be involved in RM, and estrogen influences the components of the hemostatic system, we investigated any relationship between these polymorphisms and fibrinogen, protein C (PC), protein S (PS), and antithrombin (AT) activity.
Subjects and Methods

Subjects
The institutional Ethics Committee at the State University of Campinas (UNICAMP) approved the study. Informed consent was obtained from all of the subjects involved in the study. The subjects with RM were from the Recurrent Miscarriage Outpatient Clinic in the Department of Gynecology of the Faculty of Medical Sciences at UNICAMP. RM was diagnosed when women had 3 or more RMs accompanied by vaginal elimination of a fetus weighing less than 0.5 kg, with or without vital signs, and/or a gestational age of less than 20 weeks. Genetic/chromosomal abnormalities and gynecological/obstetric alterations were excluded as etiologic factors for RM, and only patients with idiopathic RM were selected to participate in this study.
Thrombophilia was investigated in these subjects by the determination of PC, PS, AT, factor V:Q 506 , G20210A mutation in the prothrombin gene, and C677T in the methylene tetrahydrofolate reductase (MTHFR) gene. Antiphospholipid syndrome (AS) was investigated by detection of lupic anticoagulant (Russell's viper venom and caul clotting time) and IgM and IgG anticardiolipin antibodies.
The controls were from the Family Planning Outpatient Clinic at the Department of Gynecology of the Faculty of Medical Sciences, UNICAMP, and were classified according to ethnic origin. The criteria for inclusion were 2 or more successful pregnancies in which the child weighed more than 2.5 kg and did not die within the first 28 days of life. The exclusion criteria included a history of fetal death of unknown cause, thromboembolic disease, hypertension, or problems during past pregnancies, and low birth weight babies.
Plasma Assays
Collected blood was mixed with sodium citrate (1:10), and the plasma was stored at −80°C. AT was determined by an amydolytic assay (Biomérieux, Hazelwood, MO). PC (Trinity Biotech, Jamestown, NY), PS (Trinity Biotech), and fibrinogen levels (Biomérieux) were determined using commercially available coagulometric kits.
Molecular Analysis
For DNA analysis, blood was collected into 10% ethylenediaminetetraacetic acid (anti-coagulated) and kept at 4°C. Genomic DNA was extracted from peripheral blood leukocytes using a standard phenol/ chloroform method.
The c.454-397T>C and c.454-351A>G polymorphisms in the ESR1 gene were detected by polymerase chain reaction intron 1 amplification and PvuII or XbaI digestion, respectively. 13 The 1082G>A and 1730G>A polymorphisms in the ESR2 gene were detected by polymerase chain reaction amplification and RsaI and AluI digestion, respectively. The first is located in the ligand-binding domain of exon 5 and the second in the 3′-untranslated region of exon 8, respectively. 11 Factor V:Q 506 , G20210A mutation in the prothrombin gene, and C677T in the MTHFR were screened as previously described. 14, 15 
Statistical Analysis
The prevalence of genotypes, allele frequency, and haplotypes were determined by using the standard χ 2 or Fisher exact tests. The differences were considered statistically significant for P values < .05. The Wilcoxon rank-sum test was used to assess continuous variables. Statistical analyses were performed with S-Plus 2000 software (Mathsoft Inc, Seattle, WA). Odds ratios and 95% confidence intervals were used to compare categorical variables.
Results
The control group comprised 139 women, 110 Caucasians and 29 African Brazilians, between 16 and 58 years of age (median ± SD, 31 ± 8.6 years). All genotype frequencies were in Hardy-Weinberg equilibrium. Table 1 shows allele frequency and genotype prevalence of polymorphisms according to ethnic group. The prevalence of the A allele of the 1730G>A polymorphism (P = .01) and of AA genotype of the 1730G>A polymorphism (P = .04) was significantly increased in Caucasians when compared with African descendants.
The study included 75 women with RM, between 19 and 40 years of age (median ± SD, 30.1 ± 5.2 years): 54 Caucasians and 21 African Brazilians. We matched 75 of the 139 controls with RM patients according to age and ethnicity.
Except for 1082G>A, the sample size was adequate to detect any risk associated with other ESR genotypes. Allele frequency, genotype, and haplotype distributions of the ESR1 and ESR2 polymorphisms were not significantly different between controls and subjects with RM.
Genotype distributions showed no correlation with PC, PS, and AT activity. The fibrinogen concentration was lower in the controls with the GG genotype (300 mg% ± 63 mg%; n = 9) compared with those with GA or AA genotypes (365 mg% ± 102 mg%; n = 66; P = .0384) of the ESR1 c.454-351A>G polymorphism.
Screening identified 27 RM patients with thrombophilia: 10 with the C677T MTHFR homozygous mutation; 1 with G20210A prothrombin mutation and AS; 2 with factor V:Q 506 ; 2 with PC deficiency; 1 with AT deficiency and AS; 1 with Factor V:Q 506 and PS deficiency; and 10 with AS. Ten controls were found to have the C677T MTHFR homozygous mutation, and 1 had the G20210A mutation. There was no difference in ESR1 and ESR2 genotype or haplotype between RM patients with and without thrombophilia and controls. Antithrombin was significantly decreased in subjects with RM (98% ± 10%) compared to controls (109% ± 14%; P < .001). PC was significantly decreased in the subjects with RM (90% ± 15%) compared to controls (113% ± 42%; P = .001). The prevalence of heterozygosity for the MTHFR was significantly increased in the subjects with RM (63.1%) compared to controls (36.9%).
Discussion
RM is a multifactorial disorder, and several candidate genes for this disease have been investigated by studies using polymorphic genetic markers. The phenotypic effects of polymorphisms are based on direct genetic effects, gene-gene interactions, as well as gene-environment interactions. 16 During the past decade, individual genetic variability with respect to thrombophilic and vasoactive genes has been described as a significant contributor to pregnancy complications with variations depending on ethnic background. 17 As such, the polymorphisms in the estrogen receptors influence vascular tone and flow and could result in a corresponding phenotypic difference in estrogen-dependent events, including those involved in pregnancy maintenance. Furthermore, we searched for an interaction between ESR polymorphisms and RM.
The prevalence of ESR polymorphisms in this Brazilian population was different from that found in other studies. Even though slight ethnic differences in genotype distributions of the c.454-397T>C and c.454-351A>G restriction fragment length polymorphisms have been described, important variations have been observed concerning c.454-397T>Cc.454-351A>G haplotypes. There was a difference between our results when Caucasians were compared, 9 with a decreased prevalence of the TA haplotype in our population. Despite the classification of Caucasians by physical traces and clinical history, miscegenation can be underestimated. The prevalence of ESR1 haplotypes was similar only to that described in African Americans. 18 The prevalence of 1082G>A and 1730G>A polymorphisms was similar when compared to other Caucasian populations. [19] [20] [21] In contrast, the prevalence was different from that for an Asian population. 11, 22 Our results highlight the importance of determining the prevalence of polymorphisms in the normal population, which can be variable depending on the ethnicity and the background of patients. When we compared the prevalence of ESR1 and ESR2 polymorphisms between RM patients with and without thrombophilia and controls, no differences were observed.
Various studies in diverse ethnic populations have documented the influence of thrombophilia on adverse pregnancy outcomes. 17 We searched for a synergistic or additive effect between the ESR polymorphisms and thrombophilia, as estrogen can exert its action through hemostasis alterations. However, this hypothesis could not be confirmed in our study.
Furthermore, estrogen may alter hepatic expression of the genes for several coagulation and fibrinolytic proteins acting by estrogen receptors. Because these polymorphisms could have a functional effect on the action of these receptors, a correlation with PC, PS, AT, and fibrinogen levels was investigated. Controls with the GG genotype of the c.454-351A>G polymorphism presented lower fibrinogen concentrations when compared with individuals with GA and AA genotypes.
Recently Schuit et al 4 described an increased risk of myocardial infarction and ischemic heart disease, independent of known cardiovascular risk factors, in postmenopausal women who carry the c.454-351A allele. Our result demonstrating decreased fibrinogen levels in women carriers of the GG genotype of c.454-351A>G polymorphism may be one of the explanations for this finding, because fibrinogen is an established risk factor for cardiovascular disease.
Because we did not find any difference between the prevalence of this polymorphism in controls and RM patients, and a relationship between fibrinogen levels and this polymorphism has been demonstrated, our data suggest that fibrinogen does not play a role in recurrent abortion. Despite our hypothesis that some haplotypes could be a risk for RM, this finding was not observed. The mechanism by which these polymorphisms influence the action of estrogen receptors is not entirely known, but they may not affect the pregnancy maintenance.
In conclusion, our results demonstrate a difference in the genotype prevalence of ESR2 gene polymorphisms between women of Caucasian and African Brazilian descent. The GG genotype of the ESR1 c.454-351A>G polymorphism was associated with a low fibrinogen concentration in the control group. Our data suggest that ESR1 and ESR2 polymorphisms are not involved in RM.
